More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for...

|About: Bio-Reference Laboratories,... (BRLI)|By:, SA News Editor

More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for lab tests could disproportionately hurt BRLI due to its exposure to blood-based cancer tests — rates for lymphoma tests could rise 70% or more, analysts say. Also moving on the news is Quest Diagnostics (DGX +1.4%) which William Blair thinks will be the least affected, while shares of Neogenomics (NEO -15.4%) plummet on above average volume.